UNSPSC 51291712: Venlafaxine hydrochloride

This classification denotes an antidepressant agent with the molecular formula C17H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D7RX5A8MO, chemically known as wy-45,030 but more generally known as venlafaxine hcl, which bears US NIH Compound Identifier 62923. European Medicines Agency schedules Venlafaxine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05087MIG. Most nations, for tariff and trade purposes, schedule venlafaxine hydrochloride under HS 29225000 and SITC 51467.

As of Q4 2014, VENLAFAXINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Venlafaxine hydrochloride bears US NLM identifiers UMLS ID C0771200 and NCI Concept Code C29540. SMILES: CN(C)CC(C1CCC(CC1)OC)C2(CCCCC2)O.CL.

UNSPSC 51291712 Venlafaxine hydrochloride is a Commodity code representing a specific antidepressant medication; however, the recent state and local opportunities posted under this code show minimal alignment with venlafaxine itself. The three recent solicitations span broader pharmaceutical procurement categories—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with OTC products—rather than a single active pharmaceutical ingredient. State and local governments buying under this code are acquiring medications through health departments, cooperative purchasing alliances, and health and human services commissions that manage pharmacy benefits, community health programs, and employee group health plans. The work consists of establishing supply agreements with manufacturers and wholesalers, meeting FDA and Drug Supply Chain Security Act compliance requirements, maintaining authorized distributor relationships, and fulfilling quarterly or ongoing delivery schedules to designated health facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to inform future formal procurement strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a proposals due date of March 26, 2026 and July 1, 2026 contract effectiveness; this RFP covers participating state and local facilities across Minnesota and Oregon and requires vendors to work with three authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC.